Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide.

Company profile
Ticker
TRIB
Exchange
Website
CEO
Ronan O'Caoimh
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
TRIB stock data
Calendar
25 May 22
2 Jul 22
31 Dec 22
Financial summary
Quarter (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q1 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0 |
Total shares | 0 |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
Abon, Acon, add, advent, Aesku, Affinion, aggressively, albeit, Allere, altogether, anniversary, Architec, bad, Bejing, BioLine, Biosensor, catching, chair, Chairperson, Chembio, consecutive, contrast, covenant, customary, Dan, DCA, deploying, destabilised, devote, digit, discourage, disgorgement, doubtful, drawdown, drawn, easing, endeavor, envisaged, euroimmun, exceptionally, extinguished, fear, flex, founder, Goldsand, Guaranty, harmonized, headcount, inbound, incarceration, inova, Jeon, junior, Kekedjian, keyboard, Kim, Korean, laundering, lessening, LIBOR, mandatorily, MHRA, Michael, MiCo, monthly, NaN, normalisation, normalised, nurse, outbound, paper, PATRIOT, persisted, prioritising, published, puttable, ramped, regain, Russia, SD, Sebia, shift, Soo, Sung, TinaQuant, trailing, twelve, unchanged, uncured, unrestricted, unusually, VTM, VWAP, Wanta, widespread, Wondf
Removed:
AB, Abram, accelerated, Accutrend, advanced, Alto, AMPLICOR, Ampliscreen, analyzed, apportioned, Athena, Atlanta, AxSYM, Barco, Beckman, BEP, Biosite, Burger, Cardiolipin, cautionary, Centaur, choice, coagulation, concentrate, Conformit, Coulter, creating, debarment, Diego, dissolution, dominant, enabling, enrollment, Enzygnost, ETIMAX, freedom, Geographically, Georgia, gold, IFRIC, IMI, Immulite, IMx, indenture, Inv, Konelab, labeling, Legionella, lent, Liasion, liquid, Lorrelle, modifying, netted, notional, Ortho, OTC, Palo, Pineview, Qualitative, Quant, quantitative, remunerated, repealing, replacing, San, Sharon, stable, Tina, Triag, unigold, unparalleled, vast, virtue, Wampole, xiii
Financial reports
Current reports
6-K
Trinity Biotech Announces Quarter 1 2022 Financial Results
1 Jul 22
6-K
Trinity Biotech Announces CE Mark of its 10-Minute Covid-19 Antigen Test
23 May 22
6-K
Trinity Biotech Announces the Successful Closing of its
9 May 22
6-K
Trinity Biotech Announces Quarter 4 and Fiscal Year 2021
11 Apr 22
6-K
Trinity Biotech Announces A $45 Million Strategic Investment And
11 Apr 22
6-K
Current report (foreign)
11 Feb 22
6-K
Trinity Biotech Announces The Successful Closing of its Debt Refinancing
28 Jan 22
6-K
Trinity Biotech Announces That Its Shareholders Have
25 Jan 22
6-K
Current report (foreign)
6 Jan 22
6-K
Current report (foreign)
23 Dec 21
Registration and prospectus
424B3
Prospectus supplement
26 May 22
F-3
Shelf registration (foreign)
16 May 22
S-8
Registration of securities for employees
12 Feb 21
F-3
Shelf registration (foreign)
6 Jul 20
F-3
Shelf registration (foreign)
21 Apr 15
S-8
Registration of securities for employees
10 Apr 14
S-8
Registration of securities for employees
21 Jun 12
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Apr 11
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Apr 11
S-8
Registration of securities for employees
5 May 10
Proxies
No filings
Other
EFFECT
Notice of effectiveness
26 May 22
CORRESP
Correspondence with SEC
22 May 22
UPLOAD
Letter from SEC
22 May 22
EFFECT
Notice of effectiveness
16 Jul 20
CORRESP
Correspondence with SEC
12 Jul 20
UPLOAD
Letter from SEC
9 Jul 20
EFFECT
Notice of effectiveness
10 May 17
CORRESP
Correspondence with SEC
8 May 17
UPLOAD
Letter from SEC
26 Apr 15
UPLOAD
Letter from SEC
25 Jan 11
Ownership
SC 13G/A
TRINITY BIOTECH / RENAISSANCE TECHNOLOGIES ownership change
11 Feb 22
SC 13G
TRINITY BIOTECH / STONEHILL CAPITAL MANAGEMENT ownership change
4 Feb 22
SC 13G/A
TRINITY BIOTECH / Whitefort Capital Master Fund ownership change
16 Feb 21
SC 13G/A
TRINITY BIOTECH / STONEHILL CAPITAL MANAGEMENT ownership change
12 Feb 21
SC 13G
TRINITY BIOTECH / RENAISSANCE TECHNOLOGIES ownership change
10 Feb 21
SC 13G/A
TRINITY BIOTECH / STONEHILL CAPITAL MANAGEMENT ownership change
4 Sep 20
SC 13G/A
Trinity Biotech PLC
14 Feb 20
SC 13G/A
Trinity Biotech PLC
14 Feb 20
SC 13G/A
Trinity Biotech PLC
7 Feb 20
SC 13G/A
Trinity Biotech PLC
8 Jul 19